Funding Research to Cure Arthritis
Grant Opportunity: $100,000 annual research grants for newer MD and PhD investigators at US institutions
• One- and two-year grants
• 12-15 grants awarded per year
• $1.3 million research awards in 2017-18
• 4-Star Charity Navigator Rating 9 consecutive years
Avanos Medical is committed to creating the next generation of innovative healthcare solutions which will address our most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery.
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. The company has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical to make it a global leader in active orthopaedic healing. For more information, visit www.BioventusGlobal.com.
Bolder BioPATH, Inc. is an AALAC accredited preclinical CRO specializing in In Vivo models of Rheumatoid Arthritis, Osteoarthritis, Inflammatory Bowel Disease, and many other models of Inflammation and autoimmunity. Our goal is to provide preclinical efficacy and toxicity data that advances novel compounds to the IND/NDA stage
Boston Imaging Core Lab (BICL) is dedicated to enhancing the synergy between clinical excellence and cutting edge scientific research with a team of expert and highly specialized radiologists. BICL radiologists are among the leaders in musculoskeletal imaging with a strong focus on the application of MRI in osteoarthritis research. Our team of expert radiologists are involved in the latest innovative scientific activities across the globe. We believe that the most important component of our services lies in the expertise each member of our team brings to the company for our clients.
EMD Serono is part of the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the United States and Canada. EMD Serono has proven expertise in neurology, fertility and endocrinology, as well as a strong pipeline in oncology, immuno-oncology and neurology/immunology.
Fidia operates in numerous therapeutic areas, such as joint care, wound care, ophthalmology and regenerative medicine, providing specific treatments for commonly occurring pathologies with serious social repercussions. The development of therapies for the treatment of osteoarthritis, mostly through hyaluronan-based technologies, has always been a focus of Fidia’s R&D
GaitSmart™ is a 6-sensor system that measures key gait parameters in the full motion of walking, identifying abnormalities and monitoring changes over time. GaitSmart is partnering with Merck, GSK, Servier and leading European hospitals in the EU APPROACH project and the only gait measurement tool being used to provide a clinical endpoint for OA.
Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biotechnology company, focused on the development and commercialization of novel medicines that will improve people's lives.
InterVivo Solutions is a preclinical in vivo CRO providing research services to the pharmaceutical and animal health industries using translational animal models for efficacy, pharmacokinetics, safety and toxicology. InterVivo’s natural Aged Beagle model of osteoarthritis provides a uniquely translational tool for pre-clinical testing of therapeutics. Studies evaluating the efficacy of therapeutics in Aged Beagles are able to provide clinically relevant readouts of both symptomatic and disease-modifying effects of therapeutic agents. As a progressive disease model, the Aged Beagle also allows longitudinal studies across various stages of disease. InterVivo specializes in neuroscience drug discovery and is unique in its offering of translational models and multi-domain services to improve the clinical success of NCEs.
Medical Metrics is an experienced, ISO 9001-certified, medical imaging core laboratory for multi-center clinical trials. We conduct independent evaluations of novel treatments for musculoskeletal disorders involving a wide array of imaging modalities and analysis techniques. Since 2000, we have supported hundreds of trials of new medical devices, drugs, and biologics for osteoarthritis pain and disease progression. For more information, please visit https://medicalmetrics.com/therapeutic-areas/orthopedics/.
Mylan is a global healthcare company focused on making high quality medicines available to everyone who needs them. Our heritage of being a provider of generic pharmaceuticals goes back to our founding in West Virginia in 1961. Today, we are passionate champions for better health around the world with a platform unmatched in the industry.
Our mission is to discover new ways to improve and extend people`s lives. Our vision is to be a trusted leader in changing the practice of medicine. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Pfizer and Lilly: Working together to advance the understanding of chronic pain. The collaboration between Pfizer and Lilly reflects the commitment of both organizations to scientific innovation in pain. Pfizer and Lilly colleagues around the world are devoting their passion and scientific expertise to advancing the understanding of chronic pain with the goal of improving patient treatment, care, and outcomes.
Samumed is a leader in medical research and development for tissue-level regeneration. With our platform's origins in small molecule-based Wnt pathway modulation, we develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology.
Servier is an international pharmaceutical company governed by a non-profit foundation, with headquarters in France. Present in 149 countries, Servier employs 21,700 people worldwide and provide princeps and high-quality generic drugs, as well as eHealth solutions. Entirely independent, Servier reinvests 25% of its turnover (princeps drugs) in R&D.
The Journal of Rheumatology is an independent, international medical journal founded by Dr. Metro Ogryzlo in 1974. The Journal publishes timely, original, peer-reviewed research articles on clinical subjects in rheumatology and related fields. Accessible in print and online, The Journal of Rheumatology is dedicated to impacting practicing physicians worldwide.
Founded in France in 1847, The Thuasne Group is one of Europe’s oldest, largest and most respected orthopaedic companies, specializing in wearable medical devices. Thuasne has over 1,800, employees and subsidiary companies throughout Europe. The Action Reliever osteoarthritis knee brace is the latest in a long line of premium, innovative new products which Thuasne are famed for.
TLC is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need. TLC’s lead program, TLC599, is a proprietary BioSeizer™ sustained release formulation of dexamethasone sodium phosphate intended for the treatment of osteoarthritis (OA) pain. Current intraarticular sustained release anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins. An in vivo toxicity study by staining of the cartilage showed TLC599 to be cartilage sparing compared to current treatments. In its Phase II clinical trial, TLC599 was well-tolerated and demonstrated statistically significant improvements over placebo, both through 12, 16, 20, and 24 weeks and at every scheduled visit on week 1 4, 8, 12, 16, 20, and 24. Over half of the patients treated with TLC599 maintained at least a 30% reduction in pain – over twice as many as placebo – throughout the study.